The Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) drugs in development market research report provides comprehensive information on the therapeutics under development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia). Buy the report here.

Smarter leaders trust GlobalData

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) and features dormant and discontinued products.

GlobalData tracks 45 drugs in development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) by 41 companies/universities/institutes. The top development phase for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) is preclinical with 15 drugs in that stage. The Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) pipeline has 41 drugs in development by companies and four by universities/ institutes. Some of the companies in the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) pipeline products market are: Verve Therapeutics, NewAmsterdam Pharma Company and Jiangsu Hengrui Medicine.

The key targets in the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) pipeline products market include Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.), Angiopoietin Related Protein 3 (Angiopoietin 5 or Angiopoietin Like Protein 3 or ANG 5 or ANGPTL3), and Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP).

The key mechanisms of action in the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) pipeline product include Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) Inhibitor with 17 drugs in Pre-Registration. The Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) pipeline products include five routes of administration with the top ROA being Subcutaneous and nine key molecule types in the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) pipeline products market including Gene Therapy, and Monoclonal Antibody.

Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) overview

Familial hypercholesterolemia (FH) is a genetic disorder that affects the way the body processes cholesterol. People with FH have very high levels of low-density lipoprotein (LDL) cholesterol, also known as “bad” cholesterol, in their blood. This can lead to early and severe cardiovascular diseases, such as heart attacks and strokes. FH is caused by a mutation in one or more genes that are involved in removing LDL cholesterol from the blood. The most common gene affected is LDLR, which encodes the LDL receptor protein. Other genes that can cause FH are APOB, PCSK9, and LDLRAP1. FH is inherited in an autosomal dominant pattern, which means that having one copy of the mutated gene is enough to cause the condition. People who inherit two copies of the mutated gene have a more severe form of FH. FH affects about 1 in 250 people worldwide, but the prevalence may vary depending on the population and the genetic background. FH can be diagnosed by measuring the blood cholesterol levels, examining the physical signs of cholesterol deposits (such as xanthomas and arcus corneae), and performing genetic testing to confirm the mutation. FH can be treated with medications that lower cholesterol levels, such as statins, bile acid sequestrants, ezetimibe, and PCSK9 inhibitors. Some people with FH may also need other treatments, such as LDL apheresis or liver transplantation, to reduce their risk of complications. FH also requires lifestyle modifications, such as eating a healthy diet, exercising regularly, avoiding smoking, and managing other risk factors for cardiovascular diseases.

For a complete picture of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia)’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.